RoslinCT and Ayrmid Pharma Ltd. Announce Their Intent to Enter Into a Strategic Partnership to Manufacture FDA Approved Cell Therapy Omisirge ® (omidubicel-onlv)
Ayrmid Pharma Ltd., a cell therapy pioneer working to turn cells into powerful therapeutics and RoslinCT, a world leading cell and gene therapy contract development and manufacturing organization (CDMO), today announced their intent to enter into a strategic partnership for the production of Omisirge, a commercial product for the treatment of hematologic malignancies commercialized in the US by Gamida Cell Inc, a subsidiary of Ayrmid Pharma Ltd.
It is the intent of the two companies to enter into an agreement whereby RoslinCT will perform technology transfer and commercial manufacture of Gamida Cell’s Omisirge. The cell-based product is a nicotinamide modified allogeneic hematopoietic progenitor cell therapy that was FDA approved and launched in 2023. It is the intent of the two companies that the technology transfer and commercial manufacturing will take place in RoslinCT's state-of-the-art, purpose-built cell therapy CGMP manufacturing facility in Hopkinton, MA.
“As part of our global dual sourcing strategy we are delighted to announce that we intend to work with RoslinCT on the technology transfer of Omisirge to their state-of-the-art facility in Hopkinton, MA,” said Dr Joe Wiley, Chief Executive Officer of Ayrmid. He added, “This key strategic move will allow Gamida Cell to source Omisirge for our patients from both our internal manufacturing capability and RoslinCT.”
“The dynamic interactions between the two teams are very productive and we look forward to working with the Aymrid Pharma Ltd. and Gamida Cell Inc. teams to support the production of this innovative product for their patients in the United States,” said Peter Coleman, Chief Executive Officer of RoslinCT. He added, “We’re delighted about the intent to partner with Gamida Cell and add this product to the portfolio of commercial products manufactured at RoslinCT.”
About Gamida Cell
Gamida Cell Inc, a subsidiary of Ayrmid Pharma Ltd.
Gamida Cell is a cell therapy pioneer working to turn cells into powerful therapeutics. The company’s proprietary nicotinamide (NAM) technology leverages the properties of NAM to transform cells to create allogeneic cell therapy products and candidates that are potentially curative for patients with hematologic malignancies including Omisirge, approved and launched in 2023. For additional information, please visit www.gamida-cell.com or follow Gamida Cell on LinkedIn, Twitter, Facebook or Instagram.
About RoslinCT
RoslinCT is a leading global contract development and manufacturing services organization (CDMO) focused on Advanced Cell and Gene Therapies. Established in 2006 and built upon the ground-breaking technology cloning of Dolly the Sheep at the Roslin Institute in 1997, RoslinCT has harnessed cutting-edge science to advance the development of human medicines. With a remarkable heritage in the field, the company has achieved significant milestones. These include being among one of the first in the world to produce clinical-grade human pluripotent stem cells. In collaboration with the partners, RoslinCT also developed the first CRISPR-edited cell therapy product for a major inherited disorder, taking it from early development to commercialization.
Equipped with 22 purpose-built CGMP cell therapy processing suites in Edinburgh, Scotland, and Hopkinton, Massachusetts, RoslinCT provides innovative process and analytical development, CGMP clinical and commercial manufacturing for a range of cell types for both autologous and allogeneic processes, and CGMP iPSC cell line development, gene editing, and differentiation.
With tailored CDMO solutions, RoslinCT enables partners to efficiently progress from development to commercialisation and deliver life-saving Cell and Gene Therapies worldwide. RoslinCT is a GHO Capital portfolio company. Discover more about our services at www.roslinct.com or follow RoslinCT on Linkedin, Twitter, Facebook.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250311357942/en/
Contacts
Gamida Investor and Media Contact:
e-mail: BD@Gamida-Cell.com
RoslinCT Media Contact:
Carrie Zhang
email: carrie.zhang@roslinct.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Clearwater Analytics to Acquire Beacon and Blackstone’s Bistro to Deliver Investment Intelligence Across Private Markets12.3.2025 12:30:00 EET | Press release
Clearwater Analytics (NYSE: CWAN) (“Clearwater”) today announced two strategic acquisitions, marking a major step toward transforming investment management technology. Clearwater has entered into a definitive agreement to acquire Beacon, a next-generation leader for cross-asset class modeling and risk analytics for derivatives, private credit and debt, structured products and other alternative assets. Integrated with Wilshire’s equities and fixed income risk capabilities, this powerful engine enables portfolio modeling and risk management, addressing the growing focus on private and alternative assets. With institutional investors now allocating nearly 20% of their portfolios to alternatives, the need for sophisticated risk solutions has never been greater.Beacon’s platform provides complete transparency, openness and extensibility and is used by some of the most sophisticated financial firms including PIMCO, Blackstone, multi-strategy hedge funds, insurance asset managers, banks and e
New Data Highlight the Positive Impact of Exact Sciences’ Oncotype DX ® Test on Patient Care and Healthcare Efficiency12.3.2025 11:00:00 EET | Press release
Exact Sciences, a leading provider of cancer screening and diagnostic tests, today announced the presentation of new data further reinforcing the utility of its Oncotype DX Breast Recurrence Score® test at the 19th St. Gallen International Breast Cancer Conference in Vienna, Austria. A UK study1 explored the benefits of shifting the testing point to the pre-surgery setting by utilizing Oncotype DX on breast cancer core biopsy samples instead of surgical specimens. This multi-centre, prospective, randomized controlled trial (PreDX) included 341 patients eligible for Oncotype DX testing across 17 breast cancer units. The findings showed that testing on core biopsy led to a reduction in time to treatment outcome, including a clinically meaningful eight-day reduction in time from surgery to start of adjuvant treatment. In addition, testing before surgery improved the patient experience, with a significant reduction in anxiety and depression scores. “The findings show that testing on core b
Cooler Master Introduces New PC Cases, Cooling Solutions, and Power Supplies12.3.2025 10:15:00 EET | Press release
Cooler Master, a global leader in PC components and tech lifestyle solutions, today announced a new range of products that enhance cooling efficiency, offer streamlined form factors, and deliver reliable power for diverse computing needs. From the space-conscious Ncore 100 Air case to updates in the MasterLiquid and Hyper series, Cooler Master continues its focus on performance-driven, user-friendly designs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250312344454/en/ Cooler Master Ncore 100 Air Black (Photo: Business Wire) “We’re excited to introduce a fully integrated lineup that supports PC builders at every level,” said Jimmy Sha, CEO of Cooler Master. “From the compact Ncore 100 Air case to our latest MasterLiquid and Hyper coolers, SickleFlow Edge fans, and the MWE Gold V3 PSU, each product underscores our goal of blending performance, reliability, and style into every build.” Ncore 100 Air: Compact Case for Advance
Corona Cero Becomes the Official Global Beer Sponsor of the World Surf League (WSL) in a Landmark Partnership ™12.3.2025 10:00:00 EET | Press release
Today,Corona Cero, the award-winning no-alcohol beer brand, proudly announces a new four-year partnership with the World Surf League (WSL). This marks the league's first-ever global partnership with a no-alcohol beer brand, building on its eight-year partnership with Corona. Together, Corona Cero and WSL will bring more choice for athletes and fans while embracing the laid-back spirit that defines both surfing and the Corona brand ethos. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250311996463/en/ Corona Cero x WSL Official Global Beer Sponsor (Photo: Business Wire) Following Corona Cero’s triple-digit volume growth in 2024, the WSL partnership reinforces the brand’s commitment to moderation, relaxation, and celebration. “Surfing is more than just a sport—it’s a lifestyle that embraces balance, nature, and the importance of unwinding,” said Clarissa Pantoja, Global VP of Corona. “This partnership between the WSL and Coron
Regula’s Technologies Hit the Fashion Show at Intergraf Currency+Identity in Milan12.3.2025 09:00:00 EET | Press release
Regula, a global developer of forensic devices and identity verification solutions, brought document verification to the catwalk at the annual Intergraf Currency+Identity conference. Regula’s molded lenses, magnifiers, and optical filter turrets became key design elements in a fashion show featuring iconic Milanese characters: the office worker, the curious tourist, the street performer, and the child eating gelato. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250312689530/en/ The Office Siren costume with the embellishments made of Regula’s molded lenses, generally used to enable the anti-Stokes effect for examining document security features (Photo: Regula) The Intergraf Currency+Identity conference connects technology developers with a range of institutional organizations, such as security printing companies, central banks, and law enforcement agencies from all over the world. Responding to the rising need for robust do
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom